IBS is recurrent abdominal pain with a change in stool (Rome IV). The mucosa is normal. IBD is immune-mediated injury you can see, sample, or measure. ACG 2021 (Lacy, PMID 33315591) uses fecal calprotectin or lactoferrin when IBD is on the list, not as a stand-alone 'rule-out.' van Rheenen (PMID 20634346) showed calprotectin can spare some colonoscopies. It does not make a 50 mcg/g cutoff a law, and it does not erase IBD-IBS overlap in treated Crohn's or UC.

Original GastroScholar summary card for IBD versus IBS. Not an endoscopic photograph.
Original GastroScholar summary card. Not an endoscopic photograph. This page does not invent mucosa or a calprotectin cassette.

Experienced teaching points

Clinical Pearls

  1. Blood, unexplained iron deficiency, unintentional weight loss, onset after about 45-50, and a strong IBD family history are colonoscopy indications, not Rome criteria.
  2. Calprotectin under 50 mcg/g makes active IBD unlikely in the right pretest. It does not 'decisively rule out' IBD, microscopic colitis, or celiac disease.
  3. Calprotectin 50-250 is a gray zone. Repeat, pair with CRP and the story, then decide on the scope. Do not treat a 80 as IBS forever.
  4. Quiet IBD plus IBS-like pain is common. Do not escalate a biologic for functional pain, and do not skip surveillance because the calprotectin is low.
  5. Activity without another prep: IUS. Dysplasia: IBD surveillance. IBS-D tests: biomarkers. UC drugs: treat-to-target.

GI Endoscopy · 7 min read

IBD vs IBS: Calprotectin Sorts Inflammation, It Does Not Rule Out Overlap

IBS is a positive symptom diagnosis. IBD is inflammation you can measure. Patients can have both once the mucosa is quiet.

Clinical Bottom Line

Question Practical split
IBS Positive diagnosis: recurrent abdominal pain related to defecation or a change in stool form or frequency (Rome IV). Normal mucosa. ACG 2021 (PMID 33315591).
IBD Ulceration, chronic architectural change, transmural thickening, or a complication (stricture, fistula, bleed). Needs endoscopy plus histology at diagnosis, not a calprotectin number alone.
Calprotectin A neutrophil protein. Low values make active IBD less likely and can spare colonoscopy in low-pretest adults (van Rheenen, PMID 20634346). Mid-range is not a diagnosis. High values want a look.
Overlap Treated IBD with healed mucosa still gets IBS-like pain. Treat the function. Do not escalate anti-inflammatory therapy for a normal calprotectin and a normal IUS.
Who scopes now Alarm features, age that makes neoplasia plausible, or a calprotectin that will not settle. Typical young IBS without alarm can stay off the table after a thoughtful stool screen.

Does a calprotectin under 50 rule out IBD?

No. The leftover stub on this URL said a value under 50 mcg/g "decisively" excluded active IBD. van Rheenen 2010 (BMJ, PMID 20634346) is a screening meta-analysis: in adults, a low calprotectin reduced the number of people sent to colonoscopy for suspected IBD. Sensitivity is high at 50 mcg/g. It is not 100%. Timing (steroids, NSAIDs, bloody stool, sample quality) and pretest matter. Microscopic colitis and celiac disease are not calprotectin diseases. ACG 2021 (PMID 33315591) puts calprotectin or fecal lactoferrin in the IBS workup when IBD is the differential, then stops. It does not replace colonoscopy when the story is wrong.

Night stools happen in IBS. They also happen in IBD. Blood does not. Unexplained iron deficiency does not. New symptoms after 50 do not get a Rome label without a look.

What about patients who already have IBD?

Once the diagnosis is IBD, calprotectin is a monitoring tool, not a personality test. A flare workup still wants the question: is there inflammation? IUS or a flexible sigmoidoscopy can answer that without a full prep. If the mucosa and the wall are quiet, the pain may be IBS sitting on top of IBD. That is overlap, not failure of the last biologic. Do not restage SCENIC technique or UC drug choice here.

Selected references

  1. Lacy BE, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116:17-44.
  2. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease. BMJ. 2010;341:c3369.

Last reviewed September 20, 2026. Written for clinicians triaging chronic abdominal pain and altered stool and deciding who needs a colonoscopy this month.

For your teaching file

Save this article as a PDF

Drop your email and we'll open a print-ready version you can save as a PDF — and you'll start getting our weekly GI endoscopy newsletter.

Save as PDF

IBD vs. IBS: Fecal Calprotectin and Functional Overlap (2026)

Enter your email — we'll open a clean print-ready version of this article. Choose Save as PDF in the print dialog to download.